To meet a current unmet medical need, we generated 15 genetically engineered mouse models that accurately reflect the key pathogenetic aspects of human multiple myeloma. By coupling mechanistic investigations and pre-clinical immunotherapy testing, these pre-clinical platforms provide knowledge that will aid the optimization of future immunotherapy clinical trial design.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Primers 3, 17046 (2017). A review article that accurately summarizes the biology, genetics and therapeutics of MM.
Dhodapkar, M. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 128, 2599–2606 (2016). A comprehensive review focused on how precursor states evolve into clinically evident myeloma.
Mateos, M.-V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438–447 (2013). An article reporting the first clinical trial that demonstrated clinical benefit of early immunotherapy in smoldering MM.
Chesi, M. et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13, 167–180 (2008). A landmark paper reporting a mouse model driven by a single genetic lesion in the Myc oncogene, which develops MM at a very late age.
Zavidij, O. et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat. Cancer 1, 493–506 (2020). A description of the composition of the BM immune microenvironment in patients with plasma cell malignancies using single-cell approaches.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Larrayoz, M. et al. Pre-clinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma. Nat. Med. https://doi.org/10.1038/s41591-022-02178-3 (2023).
Rights and permissions
About this article
Cite this article
Modeling multiple myeloma heterogeneity in mice to advance therapeutic discoveries. Nat Med 29, 549–550 (2023). https://doi.org/10.1038/s41591-022-02198-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-02198-z
